| アブストラクト | To investigate the risk of acute kidney injury (AKI) in patients with cancer following the initiation of proton pump inhibitors (PPIs) and potassium-competitive acid blocker (PCAB), considering sex and anti-cancer drug use. We conducted a self-controlled case-series study using the Japan Medical Data Center claims data from 12422 patients with cancer who were prescribed PPIs or PCAB between January 2017 and December 2019. Considering the timing of PPI or PCAB, control period (days -120 to -1), risk period 1 (days 0 to +30), and risk period 2 (days +31 to +365) were defined. To assess the incidence rate ratio (IRR) and 95% confidence interval (CI) as the risk ratio, we adjusted for anti-cancer drugs to assess the risk of AKI. Additionally, we also examined sex differences to identify the risk of AKI. AKI was observed in risk period 1 [2.05 (1.12-3.72), p = 0.0192], but a slight reduction was noted in risk period 2 [0.60 (0.36-1.00), p = 0.0481]. A sex-specific increase in the risk of AKI was observed only in males during risk period 1 [2.18 (1.10-4.32), p = 0.0260], with a reduction in risk period 2 [0.48 (0.26-0.89), p = 0.0200]. We identified an increased risk of AKI in patients with cancer starting PPIs or PCAB particularly in males within 30 d after PPI or PCAB initiation, emphasizing the need for vigilant monitoring and management of AKI in this patient population. |
|---|
| ジャーナル名 | Biological & pharmaceutical bulletin |
|---|
| Pubmed追加日 | 2024/2/26 |
|---|
| 投稿者 | Suzuki, Kosuke; Watanabe, Ayako; Kiryu, Yoshihiro; Inoue, Eisuke; Momo, Kenji |
|---|
| 組織名 | Department of Hospital Pharmaceutics, School of Pharmacy, Showa University.;Department of Pharmacy, Showa University Hospital.;Department of Pharmacy, Showa University Koto Toyosu Hospital.;Department of Pharmacy, M&B Collaboration Medical corporation Hokuetsu Hospital.;Showa University Research Administration Center, Showa University. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38403662/ |
|---|
